Athena Athena

X
[{"orgOrder":0,"company":"Help Therapeutics","sponsor":"Ming Bioventures","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Help Therapeutics Completes Series C Financing of 25 Million Dollars","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Help Therapeutics Announces IND Approval of First Universal iPSC-derived Cardiomyocyte Therapy for End-stage Heart Failure in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling"}]

Find Clinical Drug Pipeline Developments & Deals by Help Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in patients with worsening ischemic heart failure. HiCM-188 electrically couple with the patient's myocardium to generate contractile force (remuscularization).

            Lead Product(s): HiCM-188

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: HiCM-188

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will help the company conduct and complete clinical trials of its fully independent intellectual property development pipeline, iPSC heart cell injection, and will initiate clinical studies of immune cell therapy based on iPSC technology within the next year.

            Lead Product(s): iPSC-derived Cardiomyocyte

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Ming Bioventures

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing November 27, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY